We are live on
!
Find out more
AC
Alexandria Capital Portfolio holdings
AUM
$1.08B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
-0.02%
1 Year Est. Return
+29.48%
3 Year Est. Return
+66.81%
5 Year Est. Return
+127.84%
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
+$1.6M
(+0.15%)
Cap. Flow
-$10.6M
Cap. Flow
% of AUM
-0.98%
Top 10 Holdings %
Top 10 Hldgs %
25.11%
Holding
269
New
3
Increased
97
Reduced
102
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ex China ETF
EMXC
|
+$1.59M |
| 2 |
State Street SPDR Portfolio Short Term Treasury ETF
SPTS
|
+$1.36M |
| 3 |
Johnson & Johnson
JNJ
|
+$1.1M |
| 4 |
Vanguard Short-Term Bond ETF
BSV
|
+$890K |
| 5 |
State Street SPDR Portfolio Aggregate Bond ETF
SPAB
|
+$848K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$651K |
| 2 |
iShares MSCI India Small-Cap ETF
SMIN
|
+$555K |
| 3 |
Apple
AAPL
|
+$506K |
| 4 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$482K |
| 5 |
Nektar Therapeutics
NKTR
|
+$430K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.34% |
| 2 | Healthcare | 9.51% |
| 3 | Communication Services | 8.96% |
| 4 | Financials | 7.57% |
| 5 | Consumer Discretionary | 4.92% |
Similar funds
WAM
DIC
CCP
KFM
OAM
SIM
LBD
FMT
Alexandria Capital's Q3 2021 Portfolio in Review
As of Q3 2021, Alexandria Capital held 269 positions worth $1.08B, up 0.15% from $1.08B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Alexandria Capital's Q3 2021 filing shows 3 new, 97 increased, 102 reduced and 15 closed positions. Its largest new stake was Illinois Tool Works: 1,032 shares worth $213K. The largest sale was Alnylam Pharmaceuticals, an estimated $651K.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Healthcare and Communication Services.
- Alexandria Capital's largest Q3 2021 buy was Illinois Tool Works: 1,032 shares worth $213K.
- Alexandria Capital added most to iShares MSCI Emerging Markets ex China ETF in Q3 2021, an estimated $1.59M increase.
- Alexandria Capital's biggest Q3 2021 reduction was Alnylam Pharmaceuticals, cutting an estimated $651K.
- Alexandria Capital fully exited Nektar Therapeutics in Q3 2021, selling an estimated $430K.
- Alexandria Capital's ten largest holdings make up 25% of its $1.08B portfolio in Q3 2021.
- Alexandria Capital opened 3 new positions and closed 15 in Q3 2021.
- Alexandria Capital's portfolio value rose 0.15% quarter-over-quarter to $1.08B.
Based on Alexandria Capital's 13F filing for Q3 2021, filed 2 Dec 2021.